2025
Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes
Zohora F, Nazari M, Sinusas A. Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes. Current Cardiology Reports 2025, 27: 61. PMID: 40009333, DOI: 10.1007/s11886-025-02197-9.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter defibrillatorPositron emission tomographyImplantable cardioverter defibrillator placementMyocardial sympathetic denervationRisk stratificationSympathetic denervationIschemic heart diseaseHeart failurePrevention of sudden cardiac deathRisk stratification of patientsHeart diseaseOptimal risk stratificationLow ejection fractionStratification of patientsSympathetic nerve densityImprove risk stratificationHeart failure patientsPositron emission tomography radiotracersPredicting sudden cardiac deathPositron emission tomography tracersPrognostic benefitEjection fractionClinically practical approachNerve densityNatriuretic peptide testing in veterans hospitalized with heart failure: Potential differences by sex
Gandhi P, Runels T, Han L, Skanderson M, Bastian L, Brandt C, Hauser R, Feder S, Rodwin B, Farmer M, Bean-Mayberry B, Placide S, Gaffey A, Akgün K. Natriuretic peptide testing in veterans hospitalized with heart failure: Potential differences by sex. Heart & Lung 2025, 71: 25-31. PMID: 39970822, DOI: 10.1016/j.hrtlng.2025.02.001.Peer-Reviewed Original ResearchConceptsNatriuretic peptide testingHeart failure hospitalizationFacility characteristicsVeterans Affairs Healthcare SystemPeptide testingSex-based differencesFacility-related factorsSex-stratified modelsAssociated with increased likelihoodAssociated with decreased likelihoodHealthcare systemHF diagnosisEjection fractionCardiac comorbiditiesFailure hospitalizationClinical outcomesLogistic regressionAtrial fibrillationHeart failureVeteransClinical covariatesPatientsAdmissionSexAssociationCold and hot fibrosis define clinically distinct cardiac pathologies
Miyara S, Adler M, Umansky K, Häußler D, Bassat E, Divinsky Y, Elkahal J, Kain D, Lendengolts D, Flores R, Bueno-Levy H, Golani O, Shalit T, Gershovits M, Weizman E, Genzelinakh A, Kimchi D, Shakked A, Zhang L, Wang J, Baehr A, Petrover Z, Sarig R, Dorn T, Moretti A, Saez-Rodriguez J, Kupatt C, Tanaka E, Medzhitov R, Krüger A, Mayo A, Alon U, Tzahor E. Cold and hot fibrosis define clinically distinct cardiac pathologies. Cell Systems 2025, 16: 101198. PMID: 39970910, PMCID: PMC11922821, DOI: 10.1016/j.cels.2025.101198.Peer-Reviewed Original ResearchConceptsHeart failureMyocardial infarctionAutocrine growth factor loopsUnmet medical needCardiac fibrosisNeutralizing antibodiesReduced fibrosisTreatment strategiesMyofibroblast proliferationAcute MIFibrosis post-MICardiac pathologyFibrosisTherapeutic approachesPost-MIChronic injuryMyofibroblastsMedical needFactor loopsSex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy
Butters A, Arnott C, Sweeting J, Claggett B, Cuomo A, Abrams D, Ashley E, Day S, Helms A, Lampert R, Lin K, Michels M, Miller E, Olivotto I, Owens A, Parikh V, Pereira A, Rossano J, Ryan T, Saberi S, Stendahl J, Ware J, Atherton J, Semsarian C, Lakdawala N, Ho C, Ingles J. Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy. Circulation Genomic And Precision Medicine 2025, 18: e004641. PMID: 39851041, DOI: 10.1161/circgen.124.004641.Peer-Reviewed Original ResearchConceptsRisk of heart failureSex-specific hazard ratiosHazard ratioHypertrophic cardiomyopathyAdverse outcomesHeart failureSex interaction termsFactors associated with adverse outcomesRisk of atrial fibrillationVentricular arrhythmiasCox proportional hazards modelsSarcomeric Human Cardiomyopathy RegistryManagement of hypertrophic cardiomyopathyProportional hazards modelInvestigate sex-related differencesSex differencesHeart failure riskRisk scoreHigher heart failureModerate riskHazards modelRisk factorsCardiomyopathy RegistryDeath riskImprove outcomes
2024
SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts
Goedeke L, Ma Y, Gaspar R, Nasiri A, Lee J, Zhang D, Galsgaard K, Hu X, Zhang J, Guerrera N, Li X, LaMoia T, Hubbard B, Haedersdal S, Wu X, Stack J, Dufour S, Butrico G, Kahn M, Perry R, Cline G, Young L, Shulman G. SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts. Journal Of Clinical Investigation 2024, 134: e176708. PMID: 39680452, PMCID: PMC11645152, DOI: 10.1172/jci176708.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter type 2Heart failureKetone oxidationGas chromatography-mass spectrometryFatty acid oxidationLeft ventricular ejection fractionReduced myocardial oxidative stressVentricular ejection fractionKetone supplementationWeeks of treatmentMyocardial oxidative stressDecreased pyruvate oxidationInduce heart failurePlasma glucose levelsIn vivo effectsSGLT2i treatmentEjection fractionAssociated with improvementsAwake ratsSGLT2 inhibitionCardioprotective benefitsLiquid chromatography-tandem mass spectrometryPlasma ketonesRates of ketonizationChromatography-tandem mass spectrometrySleep Deficiency A Symptoms Perspective: Exemplars from Chronic Heart Failure, Inflammatory Bowel Disease, and Breast Cancer
Redeker N, Conley S, Hwang Y. Sleep Deficiency A Symptoms Perspective: Exemplars from Chronic Heart Failure, Inflammatory Bowel Disease, and Breast Cancer. Sleep Medicine Clinics 2024, 19: 537-548. PMID: 39455175, DOI: 10.1016/j.jsmc.2024.07.003.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsChronic DiseaseFatigueFemaleHeart FailureHumansInflammatory Bowel DiseasesSleep Wake DisordersConceptsExcessive daytime sleepinessChronic heart failureInflammatory bowel diseaseBreast cancerHeart failureBowel diseaseContributions of sleep deficiencySleep disordersSleep deficiencyPrevalence of fatigueDaytime sleepinessDaytime symptomsChronic conditionsBreastCancerDeficiencySymptomsDiseaseSleepDisordersFatiguePrognostic significance of phase analysis using SPECT myocardial perfusion imaging in heart failure: a systematic review and meta-analysis
Lee K, Han S, Ryu J, Cho S, Moon D. Prognostic significance of phase analysis using SPECT myocardial perfusion imaging in heart failure: a systematic review and meta-analysis. The International Journal Of Cardiovascular Imaging 2024, 41: 27-35. PMID: 39535673, DOI: 10.1007/s10554-024-03278-6.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac-Gated Single-Photon Emission Computer-Assisted TomographyFemaleHeart FailureHumansMaleMiddle AgedMyocardial Perfusion ImagingPredictive Value of TestsPrognosisRisk AssessmentRisk FactorsTomography, Emission-Computed, Single-PhotonVentricular Dysfunction, LeftVentricular Function, LeftConceptsLeft ventricular mechanical dyssynchronyMyocardial perfusion SPECTHF patientsCardiac deathHeart failurePrognostic significancePrognostic valueGated SPECTPerfusion SPECTPooled HRMeta-analysisHazard ratioSPECT myocardial perfusion imagingAll-causeVentricular mechanical dyssynchronyAdverse cardiac eventsMyocardial perfusion imagingAdverse cardiovascular eventsPublication biasConfidence intervalsAnalysis of SPECTSystematic reviewRandom-effects modelMechanical dyssynchronyPrognostic factorsImpact of the COVID-19 pandemic on hospital-based heart failure care in New South Wales, Australia: a linked data cohort study
McIntyre D, Quintans D, Kazi S, Min H, He W, Marschner S, Khera R, Nassar N, Chow C. Impact of the COVID-19 pandemic on hospital-based heart failure care in New South Wales, Australia: a linked data cohort study. BMC Health Services Research 2024, 24: 1364. PMID: 39516863, PMCID: PMC11545568, DOI: 10.1186/s12913-024-11840-0.Peer-Reviewed Original ResearchConceptsHeart failure careNew South WalesHospital admissionHealth service utilisationAdministrative health recordsPrimary diagnosis of heart failureData cohort studyRate of admissionPre-pandemicHealth of patientsSouth WalesCOVID-19 pandemicHospital utilisationService utilisationHealth recordsED presentationsMortality dataDiagnosis of heart failureCOVID-19 burdenEmergency departmentCohort studyPrimary diagnosisData collectionCareAustralian dataNatural Language Processing of Clinical Documentation to Assess Functional Status in Patients With Heart Failure
Adejumo P, Thangaraj P, Dhingra L, Aminorroaya A, Zhou X, Brandt C, Xu H, Krumholz H, Khera R. Natural Language Processing of Clinical Documentation to Assess Functional Status in Patients With Heart Failure. JAMA Network Open 2024, 7: e2443925. PMID: 39509128, PMCID: PMC11544492, DOI: 10.1001/jamanetworkopen.2024.43925.Peer-Reviewed Original ResearchConceptsFunctional status assessmentArea under the receiver operating characteristic curveClinical documentationElectronic health record dataHF symptomsOptimal care deliveryHealth record dataAssess functional statusStatus assessmentClinical trial participationProcessing of clinical documentsFunctional status groupCare deliveryOutpatient careMain OutcomesMedical notesTrial participantsNew York Heart AssociationFunctional statusQuality improvementRecord dataHeart failureClinical notesDiagnostic studiesStatus groupsMetabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction
Selvaraj S, Patel S, Sauer A, McGarrah R, Jones P, Kwee L, Windsor S, Ilkayeva O, Muehlbauer M, Newgard C, Borlaug B, Kitzman D, Shah S, Margulies K, Husain M, Inzucchi S, McGuire D, Lanfear D, Javaheri A, Umpierrez G, Mentz R, Sharma K, Kosiborod M, Shah S. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circulation Heart Failure 2024, 17: e011980. PMID: 39421941, PMCID: PMC11634023, DOI: 10.1161/circheartfailure.124.011980.Peer-Reviewed Original ResearchMeSH KeywordsAgedBenzhydryl CompoundsBiomarkersClinical Trials, Phase IV as TopicFatty AcidsFemaleGlucosidesHeart FailureHumansMaleMetabolomicsMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicSodium-Glucose Transporter 2 InhibitorsStroke VolumeTreatment OutcomeVentricular Function, LeftConceptsHeart failureBranched-chain amino acidsEnd pointsEjection fractionLeft ventricular ejection fraction spectrumMetabolite factorsMetabolic effectsSpectrum of ejection fractionSGLT2 inhibitor dapagliflozinReduced ejection fractionHF-related outcomesEjection fraction spectrumMechanisms of benefitDEFINE-HFAcid metabolismInhibitor dapagliflozinOverall cohortMetabolomic profilesLVEFMetabolic signaturesRandomized trialsDapagliflozinHF subtypesFatty acid metabolismAmino acid metabolismSequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?
Hu J, Schwann A, Tan J, Nuqali A, Riello R, Beasley M. Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter? Heart Failure Clinics 2024, 20: 373-386. PMID: 39216923, DOI: 10.1016/j.hfc.2024.06.004.Peer-Reviewed Original ResearchCardiomyopathy‐Associated Chronic Heart Failure in Infants Aged <1 Year: A Prospective Observational Cohort Over 5 Years in Northern China
Ding W, Wang B, Hong J, Lu L, Xiao Y, Shan G, Myers C, Yu Q, Spurney C, Li Z, Han L. Cardiomyopathy‐Associated Chronic Heart Failure in Infants Aged <1 Year: A Prospective Observational Cohort Over 5 Years in Northern China. Journal Of The American Heart Association 2024, 13: e029121. PMID: 39344650, PMCID: PMC11681489, DOI: 10.1161/jaha.122.029121.Peer-Reviewed Original ResearchConceptsBundle-branch blockHeart failureVentricular noncompactionReduced left ventricular ejection fractionInfants aged <1 yearPatients up to 5Infants aged <1Pediatric heart centersOutcomes of infantsPresence of left bundle-branch blockVentricular ejection fractionLeft ventricular noncompactionEjection fraction groupChronic heart failureProspective observational studyYear of diagnosisChinese pediatric populationSecondary to cardiomyopathyProspective observational cohortIncreased heart sizeFavorable predictorsBaseline LVEFEjection fractionNo significant differenceMedical therapyHuman induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient
Tatekoshi Y, Chen C, Shapiro J, Chang H, Blancard M, Lyra-Leite D, Burridge P, Feinstein M, D'Aquila R, Hsue P, Ardehali H. Human induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient. ELife 2024, 13: rp95867. PMID: 39331464, PMCID: PMC11434618, DOI: 10.7554/elife.95867.Peer-Reviewed Original ResearchConceptsHuman induced pluripotent stem cell-derived cardiomyocytesPluripotent stem cell-derived cardiomyocytesStem cell-derived cardiomyocytesCell-derived cardiomyocytesUptake in vitroHIV viremiaDiastolic dysfunctionHIV patientsCardiomyocyte relaxationSarcoplasmic reticulumSGLT2 inhibitorsHeart failurePotential new interventionsInflammatory cytokinesAnimal modelsHFpEFStudy molecular mechanismsMito-TEMPOCardiomyocytesCytokinesHIVPatientsRelaxation defectsPLWHSerumEffects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure Results From SOLOIST-WHF
Bhatt A, Bhatt D, Steg P, Szarek M, Cannon C, Leiter L, McGuire D, Lewis J, Riddle M, Voors A, Metra M, Lund L, Testani J, Wilcox C, Davies M, Pitt B, Kosiborod M. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure Results From SOLOIST-WHF. Journal Of The American College Of Cardiology 2024, 84: 1078-1088. PMID: 39260929, DOI: 10.1016/j.jacc.2024.06.036.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2Effect of sotagliflozinKCCQ-12 scoreKCCQ-12Heart failureSOLOIST-WHFPrimary endpointSodium-glucose cotransporter 2 inhibitionLeft ventricular ejection fractionWorsening heart failureBaseline to monthVentricular ejection fractionHealth statusWorsening HFKansas City Cardiomyopathy Questionnaire-12Ejection fractionSecondary endpointsCotransporter 2Randomized patientsClinical characteristicsHF hospitalizationPlaceboCardiovascular deathHF episodeSotagliflozinMyocardial Recovery in the Systemic Context: A Philosophic Shift for the Heart Failure Subspecialty to Optimize Patient Care
Kapoor A, Kayani J, Saad M, Lala A. Myocardial Recovery in the Systemic Context: A Philosophic Shift for the Heart Failure Subspecialty to Optimize Patient Care. Methodist DeBakey Cardiovascular Journal 2024, 20: 98-108. PMID: 39184157, PMCID: PMC11342849, DOI: 10.14797/mdcvj.1416.Peer-Reviewed Original ResearchConceptsDelivery of careImprove functional capacityPatient careHealthcare systemFunctional capacityHeart failure managementCareHeart failureAging populationFrequent hospitalizationsMedical optimizationIncreased prevalenceModern patientsHolistic definitionMortality rateAmbulatory heart failureSpectrum of diseasesPhilosophical shiftFailure managementClinical outcomesMyocardial recoverySystem contextHealthcareSubspecialtyPatientsDapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
Tada A, Burkhoff D, Naser J, Harada T, Pourmussa B, Reddy Y, Jensen M, Carter R, Demmer R, Testani J, Chirinos J, Borlaug B. Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial. Circulation 2024, 150: 997-1009. PMID: 39101201, PMCID: PMC11433515, DOI: 10.1161/circulationaha.124.068788.Peer-Reviewed Original ResearchConceptsSystemic arterial complianceEffects of dapagliflozinStressed blood volumeVenous capacitanceBlood volumePeak exerciseArterial complianceHemodynamic congestionHeart failureEstimating stressed blood volumeImproved systemic arterial complianceInvasive hemodynamic exercise testingSodium-glucose cotransporter-2 inhibitorsSystolic BPPulmonary capillary wedge pressureHemodynamic exercise testingCapillary wedge pressureCotransporter-2 inhibitorsSystemic vascular resistanceImproving clinical outcomesTotal blood volumeRadial artery pressureSimultaneous echocardiographyEjection fractionFluid-filled catheterMaternal Bereavement and Heart Failure Risk of the Offspring
Goldstein S, Pastor T, Samsky M. Maternal Bereavement and Heart Failure Risk of the Offspring. JACC Heart Failure 2024, 12: 1363-1364. PMID: 39111951, DOI: 10.1016/j.jchf.2024.06.002.Peer-Reviewed Original ResearchSemaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
Deanfield J, Verma S, Scirica B, Kahn S, Emerson S, Ryan D, Lingvay I, Colhoun H, Plutzky J, Kosiborod M, Hovingh G, Hardt-Lindberg S, Frenkel O, Weeke P, Rasmussen S, Goudev A, Lang C, Urina-Triana M, Pietilä M, Lincoff A, Investigators S, Abe M, Abhaichand R, Abhayaratna W, Abhyankar A, Abidin I, Assi H, Mendoza J, Adas M, Agaiby J, Agarwal D, Agha M, Ahmed A, Ahtiainen P, Aigner E, Ajay N, Ali N, Al-Karadsheh A, Allison R, Allison D, Alpenidze D, Altuntas Y, Al-Zoebi A, Ambuj R, Amerena J, Anderson R, Ando T, Andrews R, Antonova E, Appel K, Arantes F, Araz M, Arbel Y, León J, Argyrakopoulou G, Ariani M, Mendoza M, Arif A, Arneja J, Aroda V, Aronne L, Arstall M, Asamoah N, Asanin M, Audish H, Avram R, Badat A, Badiu C, Bakdash W, Bakiner O, Bandezi V, Bang L, Bansal S, Baranyai M, Barbarash O, Barber M, Barnum O, Rochette G, Bashkin A, Baum S, Bays H, Ruiz A, Beckowski M, Beerachee Y, Bellary S, Belousova L, Berk M, Bernstein M, Berra C, Beshay I, Bhagwat A, Bhan A, Biggs W, Billings L, Bitar F, Block B, Bo S, Bogdanski P, Bolshakova O, Boshchenko A, Bosworth H, Lopez R, Bôttcher M, Bourgeois R, Brautigam D, Breton C, Broadley A, Brockmyre A, Brodie S, Bucci M, Budincevic H, Budoff M, Buffman B, Buljubasic N, Buranapin S, Burgess L, Burguera B, Buriakovska O, Buscemi S, Busch R, Buse J, Buynak R, Byrne M, Caceaune E, Bonfanti A, Calinescu C, Call R, Varzic S, Cannon K, Capehorn M, Cariou B, Carr J, Carrillo-Jimenez R, Casas M, Castro A, Celik A, Cercato C, Cermak O, Y J, Chacon C, Chaicha-Brom T, Chandra S, Chettibi M, Chevts J, Christopher J, Chrustowski W, Cif A, Clark R, Clark W, Clifford P, Coetzee K, Cogni G, Colao A, Colquhoun D, Concha M, Condit J, Constance C, Constantin C, Constantinescu S, Corbett C, Cornett G, Correia M, Cortinovis F, Cosma D, Creely S, Cross D, Curtis B, Czochra W, Daboul N, Dagdelen S, D'agostino R, Dang C, Datta S, Davuluri A, Dawood S, De Jong D, De La Cuesta C, De Los Rios Ibarra M, De Pablo C, De Pauw M, Dela Llana A, Delibasic M, Delic-Brkljacic D, Demicheli T, Denger R, Desai D, Desai P, Desouza C, Dicker D, Djenic N, Dobson S, Doi M, Doran J, Dorman R, Dotta F, Dukes C, Duronto E, Durst R, Dvoryashina I, Ebrahim I, Eggebrecht H, Egstrup K, Ekinci E, Eliasson B, Eliasson K, Enache G, Enculescu D, English P, Ermakova P, Ershova O, Ezaki H, Ezhov M, Farias E, Farias J, Farsky P, Ferreira D, Filteau P, Finneran M, Folkens E, Fonseca A, Fonseca L, Fordan S, Fourie N, França S, Franco D, Franek E, Friedman K, Frittitta L, Froer M, Fuckar K, Fujii K, Fujita R, Fukushima Y, Fulat M, Fulwani M, Gajos G, Galyavich A, Gambill M, Gandotra D, Winston G, Hernandez P, Reza R, Garg N, Garg S, Garvey W, Garza J, Gatta-Cherifi B, Gelev V, Geller S, Geohas J, Georgiev B, Ghazi A, Gilbert M, Gilinskaya O, Gislason G, Yavuz D, Albarrán O, Gordeev I, Gorton S, Goudev A, Valderhaug T, Groenemeijer B, Gul I, Gullestad L, Gurieva I, Guseva G, Hagenow A, Haluzik M, Halvorsen S, Hammoudi N, Hanaoka K, Hancu N, Hanusch U, Harris K, Harris B, Hartleib M, Hartman A, Hata Y, Heimer B, Herman L, Herzog W, Hewitt E, Heymer P, Hiremath S, Hjelmesaeth J, Høgalmen R, Høivik H, Holmer H, Horoshko O, Houser P, Hove J, Hsieh I, Hulot J, Hussein Z, Ilashchuk T, Ilveskoski E, Ipatko I, Iranmanesh A, Isawa T, Issa M, Iteld B, Iwasawa T, Jabbar D, Jackson R, Jackson-Voyzey E, Jacob S, Jaffrani N, Jardula M, Jastreboff A, Jensen S, Jerkins T, Jimenez-Ramos S, Singh S, Johnson W, Joyce J, Jozefowska M, Jugnundan P, Jungmair W, Jurowiecki J, Kadokami T, Kahali D, Kahrmann G, Kaiser S, Kalmucki P, Kanadasi M, Kandath D, Kania G, Kannan J, Kapp C, Karczmarczyk A, Kartalis A, Kaser S, Kasim S, Kastelic R, Kato T, Katova T, Kaul U, Kautzky-Willer A, Kawanishi M, Kayikcioglu M, Kazakova E, Keeling P, Kempe H, Kereiakes D, Kerneis M, Keski-Opas T, Khadra S, Khaisheva L, Kharakhulakh M, Khlevchuk T, Khoo J, Kiatchoosakun S, Kinoshita N, Kinoshita M, Kitamura R, Kiyosue A, Klavina I, Klein E, Klimsa Z, Klonoff D, Klug E, Kobalava Z, Kodera S, Koga T, Kokkinos A, Koleckar P, Könyves L, Koren M, Kormann A, Kostner K, Kreutzmann K, Krishinan S, Krishnasamy S, Krivosheeva I, Kruljac I, Kubicki T, Kuchar L, Kujawiak M, Kunishige H, Kurtinecz M, Lisboa H, Kushnir M, Kyyak Y, Lace A, Lakka T, Lalic N, Lalic K, Lambadiari V, Lanaras L, Lang C, Langlois M, Lash J, Latkovskis G, Lau D, Soto J, Le Roux C, Ledesma G, Lee L, Lee T, Lee K, Lehrke M, Leite S, Leksycka A, Lenzmeier T, Leonetti F, Leonidova V, Lepor N, Leung M, Levchenko O, Levins P, Levy L, Lewis M, Liberopoulos E, Liberty I, Lindholm C, Lingvay I, Linhart A, Liu M, Liu J, Lofton H, Logemann T, Lombaard J, Lombard L, Lorraine R, Lovell C, Ludvik B, Lukaszewicz M, Lupkovics G, Lupovitch S, Lupu S, Lynch M, Lysak Z, Lysenko T, Maeda H, Maeda I, Mæng M, Mahajan A, Maher V, Maia L, Makotoko E, Malavazos A, Malecha J, Malicherova E, Manita M, Mannucci E, Mareev V, Marin L, Markova T, Marso S, Martens F, Martinez C, Cano C, Martins C, Comas L, Matsumoto T, Mcdonald K, Mcgowan B, Mcgrew F, Mclean B, Mcpherson D, Torres J, Meyers P, Meyhöfer S, Raya P, Milanova M, Milicic D, Miller G, Mills R, Mîndrescu N, Mingrone G, Minkova D, Mirani M, Miras A, Mistodie C, Mitomo S, Mittal S, Miyake T, Miyamoto N, Molony D, Monteiro P, Mooe T, Moosa N, Portillo C, Villegas E, Morawski E, Morbey C, Morin R, Morisaki K, Morosanu M, Mosenzon O, Mostovoy Y, Munir I, Muratori F, Murray R, Murthy A, Myint M, Myshanych G, Nafornita V, Nagano T, Nair S, Nakhle S, Natsuaki M, Nayak B, Nibouche D, Nicholls S, Nicolau J, Nicolescu G, Nierop P, Niskanen L, Ntaios G, Nygård O, Oaks J, Obrezan A, O'donnell P, Oguri M, Oguzhan A, Oh F, Ohsugi M, Okada Y, Okayama H, Onaca A, Onaka H, Oneil P, Ong T, Ong S, Ono Y, Opsahl P, Ostrowska L, Oviedo A, Ozdogan O, Ozpelit E, Pagkalos E, Pagotto U, Páll D, Pandey A, Parkhomenko O, Parvathareddy K, Patel M, Patsilinakos S, Paul N, Pedersen S, Pereira I, Pereira E, Terns P, Perez-Vargas E, Pergaeva Y, Perkelvald A, Peskov A, Peter J, Peters K, Petit C, Petrov I, Philis-Tsimikas A, Pietilä M, Pinto F, Piros A, Piyayotai D, Platonov D, Poirier P, Pop L, Popa B, Pop-Busui R, Poremba J, Porto A, Postadzhiyan A, Pothineni R, Potu R, Powell T, Prafulla K, Prager R, Prakova-Teneva Z, Pratley R, Price H, Pulka G, Pullman J, Punt Z, Purighalla R, Purnell P, Qureshi M, Rabasa-Lhoret R, Raikhel M, Rancane G, Randeva H, Rasouli N, Pintilei D, Reyes C, Rezgale I, Rice E, Riley T, Risser J, Ristic A, Fernández M, Robbins D, Robitaille Y, Rodbard H, Plazas J, Römer T, Rosen G, Rosman A, Rossi P, Rudenko L, Ruffin O, Ruhani A, Runev N, Ruyatkin D, Ruzic A, Ryabov V, Rydén L, Saggar S, Sakamoto T, Salter T, Samal A, Samoilova Y, Sanabria H, Sancak S, Sangrigoli R, Sansanayudh N, Santini F, Saraiva J, Sardinov R, Sargeant W, Sari R, Sathananthan A, Sathyapalan T, Sato A, Sauter J, Sbraccia P, Schaap J, Schaum T, Schiele F, Scott J, Lieberman G, Segner A, Senior R, Sergeeva-Kondrachenko M, Serota H, Serusclat P, Sethi R, Shah M, Shah N, Shalaev S, Sharma R, Sharma S, Shaydyuk O, Shea H, Shechter M, Shehadeh N, Shirazi M, Shlesinger Y, Shneker A, Shutemova E, Siasos G, Siddiqui I, Sidey J, Sigal F, Sime I, Singh N, Siraj E, Sivalingam K, Skoczylas G, Smith S, Smolenskaya O, Snyder B, Sofer Y, Sofley C, Solano R, Sonmez Y, Sorokin M, González A, Sotolongo C, Soufer J, Selcukbiricik O, Spaic T, Spriggs D, Sreenan S, Stahl H, Stamatelopoulos K, Stanislavchuk M, Stankovic G, Stasek J, Steg G, Steindorf J, Stephan D, Stewart J, Still C, St-Maurice F, Stogowska-Nikiciuk B, Stoker J, Stokic E, Strzelecka A, Sturm K, Sueyoshi A, Sugiura T, Sultan S, Suplotova L, Suwanagool A, Suwanwalaikorn S, Sveklina T, Swanson N, Swart H, Swenson B, Szyprowska E, Tait G, Takács R, Takeuchi Y, Tamirisa A, Tanaka H, Tatovic D, Tellier G, Teragawa H, Teterovska D, Thomas N, Thuan J, Tinahones F, Tisheva-Gospodinova S, Toarba C, Todoriuk L, Tokmakova M, Tonstad S, Toplak H, Tran H, Tripathy D, Trusau A, Tsabedze N, Tsougos E, Tsoukas G, Tuccinardi D, Tuna M, Turatti L, Tziomalos K, Udommongkol C, Ueda O, Ukkola O, Unubol M, Urbach D, Triana M, Usdan L, Vaidya B, Vale N, Vallieres G, Van Beek A, Van De Borne P, Van Der Walt E, Van Der Zwaan C, Van Nieuwenhuizen E, Van Zyl L, Vanduynhoven P, Varghese K, Vasileva S, Vassilev D, Vathesatogkit, Velychko V, Vercammen C, Verges B, Verma S, Verwerft J, Vesela A, Veselovskaya N, Vettor R, Veze I, Vijan V, Vijayaraghavan R, Villarino A, Vincent R, Vinogradova O, Vishlitzky V, Vlad A, Vladu I, Vo A, Von Engelhardt C, Von Münchhausen C, Vorobyeva O, Vossenberg T, Vrolix M, Vukicevic M, Vyshnyvetskyy I, Wadvalla S, Wagner J, Wakeling J, Wallace J, Mohamed W, Wander G, Ward K, Warren M, Watanabe A, Weber B, Weintraub H, Weisnagel J, Welker J, Wendisch U, Wenocur H, Wierum C, Wilding J, William M, Wilson P, Wilson J, Wong Y, Wongcharoen W, Wozniak I, Wu C, Wyatt N, Wynne A, Yamaguchi H, Yamasaki M, Yazici D, Yeh H, Yotov Y, Yuan Q, Zacher J, Zagrebelnaya O, Zaidman C, Zalevskaya A, Zarich S, Zatelli M, Zeller H, Zhdanova E, Zornitzki T, Zrazhevskiy K, Zykov M, Lincoff A, Ryan D, Colhoun H, Deanfield J, Emerson S, Kahn S, Kushner R, Plutzky J, Brown-Frandsen K, Hovingh G, Hardt-Lindberg S, Tornøe C. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet 2024, 404: 773-786. PMID: 39181597, DOI: 10.1016/s0140-6736(24)01498-3.Peer-Reviewed Original ResearchConceptsReduced ejection fractionOnce-weekly subcutaneous semaglutideHistory of heart failureEjection fractionHeart failureHeart failure subtypesAtherosclerotic cardiovascular diseaseSubcutaneous semaglutideBaseline characteristicsCardiovascular diseaseEffects of once-weekly subcutaneous semaglutideNew York Heart Association statusCardiovascular outcomesInteractive web response systemIncidence of clinical eventsGLP-1 receptor agonistsHeart failure endpointsSafety of semaglutideSubtypes of heart failureWeb response systemClinical heart failureEffect of semaglutideDouble-blind mannerSerious adverse eventsPhase 3 trialEffects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction
Naser J, Tada A, Harada T, Reddy Y, Carter R, Testani J, Jensen M, Borlaug B. Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction. Circulation 2024, 149: 2026-2028. PMID: 38885297, PMCID: PMC11185269, DOI: 10.1161/circulationaha.124.069479.Peer-Reviewed Original ResearchEffect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial
Lassen M, Ostrominski J, Inzucchi S, Claggett B, Kulac I, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, Docherty K, McMurray J, Solomon S, Vaduganathan M. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial. European Journal Of Heart Failure 2024, 26: 1539-1548. PMID: 38745498, DOI: 10.1002/ejhf.3269.Peer-Reviewed Original ResearchConceptsBackground glucose-lowering therapyLeft ventricular ejection fractionGlucose-lowering therapySodium-glucose cotransporter 2 inhibitorsHeart failureClinical outcomesComposite of worsening HFPrimary outcomeInsulin useBenefits of dapagliflozinVentricular ejection fractionEffects of dapagliflozinType 2 diabetesEjection fractionRandomized patientsMetformin useConcomitant metforminCardiovascular deathFollow-upContemporary guidelinesDapagliflozinTreatment effectsDELIVER trialTreatment benefitT2D
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply